The Governance Behind Community Pharmacy Prescribing: NHS England’s 2026 Rulebook, Explained

Some people are calling NHS prescribing in community pharmacy “the Wild West.” It’s the opposite. On 31 July 2026, NHS England published a package of guidance that builds an entire governance architecture around independent prescribing in the national community pharmacy services — and most pharmacists haven’t read it. Here’s the whole thing in plain English: why it exists, the three layers, and exactly what you, your employer and your ICB now have to do.

This is the written companion to my video series on this — part one covers the professional assurance framework (your personal obligations). Watch it here, then read on for the full breakdown.

Why this package exists

From summer 2026, every new MPharm graduate qualifies as an independent prescriber at the point of registration. After the Pathfinder programme was evaluated as a success, prescribing is being baked into the community pharmacy contract itself, with prescribing due to enter the national services — Pharmacy First, the Contraception Service and Prescription Management — from autumn 2026, once the legal directions land.

Here’s the structural problem NHS England had to solve. Unlike GPs, dentists and optometrists, pharmacists have no NHS performers list — no formal admission process confirming you’re competent for a specific NHS role. That left a gap the framework names directly: the difference between fitness to practise and fitness for purpose.

The solution: three layers of assurance

Rather than one gatekeeper, NHS England distributed the assurance job across three parties. The published guidance speaks to each: a professional assurance framework for pharmacists and employers, commissioning guidance for ICBs, and a readiness letter setting deadlines and funding. Let’s take them in the order that matters to you.

Layer 1 — you, the prescriber

These are the personal obligations, and for many community pharmacists this level of structured governance — borrowed from the medical appraisal model — is genuinely new territory.

1. An annual fitness-for-purpose declarationYou complete a written declaration of your prescribing scope of practice — the conditions and patient groups you’re competent to prescribe for — and submit it to your employer, who records it. Update it annually, or sooner if your scope changes or you stop prescribing. Your scope isn’t defined by your IP annotation: the annotation says you can prescribe; the declaration says what you will. If something goes wrong outside your declared scope, that declaration is the paper trail.
2. Regular clinical supervisionRegular access to a named clinical supervisor or prescribing mentor — the framework gives one session per month as the example, so monthly is the expected norm. It doesn’t have to be a doctor; a senior or experienced prescriber works, modelled on multidisciplinary team supervision.
3. An annual prescribing appraisalAt least once a year, protected time to formally review your prescribing with your supervisor and document development areas. This is a new, additional layer — not the same as GPhC revalidation, which continues unchanged. Don’t blur the two.
4. A professional portfolioEvidence of your prescribing decisions — including the decisions not to prescribe (that phrase is deliberate; declining to prescribe is a marker of a good prescriber and protects you against complaints) — plus peer discussions, errors, audits, reflections and CPD. Not GPhC-mandated, but expected as best practice, and it can feed revalidation.
5. Annual competency self-assessmentAssess yourself each year against the RPS/Royal College of Pharmacy Prescribing Competency Framework — the national framework every prescriber, doctors included, is measured against.

Two more you must not miss: Level 3 safeguarding (adults and children) is the minimum — most community pharmacists currently sit at Level 2, so this is a real training gap to close — and indemnity that specifically covers prescribing, because standard pharmacist cover may not. Check your policy.

Layer 2 — your employer / the contractor

The employer’s job is the checks and the records. Before you deliver clinical services they need: current GPhC registration with no relevant sanctions, an enhanced DBS within the last three years, right-to-work and English-language evidence, an HPAN check (Healthcare Professional Alert Notice), two structured references (for the newly qualified, one from the DPP/foundation supervisor), evidence of training for the service, and appropriate indemnity. There’s even a route for sole traders and family businesses where independent references aren’t available — a risk assessment plus a probationary period of around three months.

Employers must keep all fitness-for-purpose records — registration, indemnity, scope declarations, authorisations — for at least five years, available to commissioners on request. And they carry duties around supervision, appraisal and development: they must support monthly supervision, structured induction for those new to prescribing, and — importantly — they must not push a pharmacist to expand scope without a clinical risk assessment and support.

Layer 3 — the ICB, the commissioner

The ICB commissions the service, holds the budget, and provides oversight. A few governance points matter to you as a prescriber:

• Full traceability. Every contractor gets an EPS prescribing cost centre; each prescriber is assigned to it by registration number, so every item is attributable to a specific prescriber, contractor and ICB budget, monitored via ePACT2 — scope adherence, formulary, high-risk medicines, antibiotics, controlled drugs, volumes, costs, outcomes and referrals.
• Conflict of interest. Contractors must assess how prescribing and dispensing by the same business will be managed, and remuneration must reward the quality of clinical decisions and outcomes, not prescription volume — NHS England directly addressing the “pharmacist prescribes, pharmacy profits” criticism.
• Digital & safety hard requirements. Clinical safety standards (DCB0129/DCB0160), EPS by default, an NHS-assured prescribing solution, records access via NCRS or GP Connect, same/next-day communication back to the GP, DSPT “Standards Met”, and CIS2/AAL3 identity with the right access before you can sign an EPS prescription.

The readiness letter is where the news hooks sit: around £51,000 per ICB for 2026/27 only to fund readiness, and onboarding targets running to 31 March 2027. The practical point: because ICBs control onboarding, compliance is the ticket to play.

What’s actually being unlocked

The governance sits on top of services you already know. Prescribing is being bolted onto the existing Pharmacy First pathways (sore throat, earache, sinusitis, infected insect bites, impetigo, shingles, and uncomplicated UTIs in women) and the Contraception Service. The change: an independent prescriber can use clinical judgement to complete the episode of care — a different antibiotic, a different dose, a patient just outside the old PGD criteria — instead of bouncing them back to the GP. There’s also prescription management (e.g. prescribing an alternative when an item is out of stock, with arrangements in place), and up to five new prescriber-only pathways under consideration — I’d say “being considered,” because they need clinical reference group sign-off before rollout.

How to prepare — and how I can help

If you’re a community pharmacist heading into this, the move now is to get your governance in order before autumn: start your portfolio, book your supervision, do your competency self-assessment, upgrade to Level 3 safeguarding, and confirm your indemnity covers prescribing. This is exactly what our GPhC & CQC compliance work supports — getting the declaration, supervision, portfolio and documentation right so onboarding is painless and your registration stays safe. (See also is community pharmacy independent prescribing worth it? and should you pay for a DPP?)

Work with me

Frequently asked questions